Navigation Links
N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Date:9/8/2010

BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR).

N6022 is the first GSNOR inhibitor to be administered to human beings. N6022 has the potential to be an important new treatment for acute exacerbations of human diseases, such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) and other inflammatory conditions.

About N6022 N6022 is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. The initial Phase 1 testing in healthy subjects is designed to evaluate the safety, tolerability and pharmacokinetics of single, increasing intravenous dosages of N6022.  Data from this first-in-man trial will provide important safety, pharmacokinetic, and biomarker information on which to base the design of subsequent trials of N6022 as well as the development of reductase dosage forms suitable for chronic administration.

Targeting GSNORGSNOR breaks down s-nitrosoglutahione (GSNO), reducing the body's pool of GSNO.  In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects.   Similarly, in the gut GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR upregulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy.  GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNORN30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, a s-nitrosothi
'/>"/>

SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
2. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
3. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
4. Abbott Completes Acquisition of Piramals Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
5. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
6. Supreme Court of Israel Rules in Favor of Sun Pharma
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Pharmacy Franchise Owners Association Taps David Mayper as Executive Director
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
11. Reportlinker Adds US Pharmaceutical Packaging Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery ... that it has raised A$19.3 million via a placement ... Europe , the U.S., Asia ... million from a share purchase plan (SPP) to be ... will be made in two tranches. "This ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... , Part of International Internet Week ... The U.S. Food and Drug Administration today completed ... Week of Action (IIWA), intended to curb illegal actions ... During the effort, the FDA,s Office of Criminal Investigations ...
... , Primary Care Doctors, Endocrinologists Feel ... N.J., Nov. 19 Nearly one-third of doctors surveyed said ... sufficient reimbursement to provide comprehensive care to their patients with ... and primary care doctors published today in American Health ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 3Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 5
(Date:7/11/2014)... The report “Probiotics Market by ... Feed), Applications (Regular, Therapeutic, Preventive Health Care) & ... Forecasts to 2019 ” defines and segments the ... of the market value of probiotic products and ... restraining factors for the global market with an ...
(Date:7/11/2014)... Global enterprises today are shifting towards the changing trend ... services offer these global enterprises a strategic method to ... rising operational costs to companies. The aim to minimize ... global market driver for expanding the managed services market ... is estimated to grow from $142.75 billion in 2013 ...
(Date:7/11/2014)... Toledo, Ohio (PRWEB) July 11, 2014 ... (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number ... in blood sugar, abdominal issues and even death from ... exposed. , According to the Times report , ... events in 2013 reported by patients was almost 14% ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... the worldwide scourge of dengue fever was somewhat successful in ... prevented dengue fever in 56 percent of the 10,000 kids ... more than 88 percent of them from severe disease. In ... sometimes death. "This vaccine has already proven to be ...
Breaking Medicine News(10 mins):Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... 1 (HealthDay News) -- Increasing daily soluble fiber intake may ... other substances linked to a host of chronic diseases, according ... found just under the skin, visceral fat is located deep ... Researchers at Wake Forest Baptist Medical Center found the way ...
... believe medical practitioners can help reduce the number of ... effectively educating their patients about the importance of mammography ... the Journal of Cancer Education , Rosalie Young, ... and Jason Booza, Ph. D., assistant professor, all from ...
... Researchers from the University of Leeds will carry out a ... or treat the spread of bowel cancer to the liver. ... of pure Eicosapentaenoic Acid (EPA) - a naturally occurring omega-3 ... oil preparations in health stores and supermarkets nationwide. Gastroenterologist ...
... (MGH) researchers have discovered the first of an entirely ... with the development of blood vessels. In a report ... /Early Edition, the investigators describe how a compound derived ... novel mechanism, to interfere with blood vessel formation in ...
... The Obama administration turned a bright spotlight on prescription ... Drug Control Policy released a national action plan and ... cover article in the July edition of the ... focus that spotlight on themselves both as major sources ...
... Bill Keevil, Head of the Microbiology Group and ... University of Southampton, has presented research into the ... on antibiotic-resistant organisms at the World Health Organization,s ... (ICPIC). ,New Insights into the Antimicrobial Mechanisms ...
Cached Medicine News:Health News:Soluble Fiber Appears Key to Trimming 'Bad Fat' 2Health News:Health providers should emphasize breast cancer screening, Wayne State University research finds 2Health News:Leeds researchers test benefit of fish oil in bowel cancer spread 2Health News:Mass. General team identifies new class of antiangiogenesis drugs 2Health News:Research examines dentists' role in painkiller abuse 2Health News:Research examines dentists' role in painkiller abuse 3Health News:Copper reduces infection risk by more than 40 percent 2
...
... accommodate a variety of applications across a ... DestinyPlus is suitable for any laboratory demanding ... a mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per ... full range of chromogenics, the AMAX DestinyPlus ...
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
Medicine Products: